Erenumab
ارنومب
🧠 Nervous SystemAnti-CGRP receptor antibody
Market / country: 🇺🇸 USA
Aimovig (US)
🧮 Dose calculator
Migraine prophylaxis · Regimen source: FDA Aimovig · 2.1
- • One SC dose per MONTH (not daily). FDA Aimovig · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Serious hypersensitivity to erenumab (anaphylaxis, angioedema). FDA Aimovig · 4
Warnings
- • Severe constipation; new or worsening hypertension. FDA Aimovig · 5
Formulations
- 70 mg/mL or 140 mg/mL autoinjector — injection 🇺🇸 USA FDA Aimovig · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Aimovig · 8.1
“Risk Summary There are no adequate data on the developmental risk associated with the use of AIMOVIG in pregnant women.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Aimovig · 8.2
“Risk Summary There are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Aimovig · 8.4
“Safety and effectiveness in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Aimovig · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)BLA761077
- DailyMed (FDA label)FDA Aimovig
- MedlinePlus (NIH)Erenumab-aooe Injection
- WHO ATC/DDDN02CD01
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Aimovig · 3FDA Aimovig · 2.1FDA Aimovig · 4FDA Aimovig · 5FDA Aimovig · SPL approval / marketing categoryFDA Aimovig · 8.1FDA Aimovig · 8.2FDA Aimovig · 8.4FDA Aimovig · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified